This roundtable discussion facilitated by Cherie Grishin, Operations and Quality Management Consultant at HemaOrigins, and Jonathan Wofford, General Manager - Biotherapies at WellSky will focus around common challenges for cell and biotherapies programs. Topics include strategies for Standard Operating Procedure (SOP) development, regulatory considerations for audits and new products, managing clinical trials and new drug applications, and planning and executing validations.